National
Court ruling deals blow to North Carolina anti-LGBT law
Gov. Pat McCrory (R-N.C.) has said he would comply with a court ruling in favor of Virginia transgender student. (Photo by Hal Goodtree; courtesy Wikimedia Commons)
A federal appeals court ruling in favor of a Virginia transgender student seeking to use school restrooms consistent with his gender identity constitutes a blow to North Carolina’s recently enacted anti-LGBT law, legal experts say.
Although the U.S. Fourth Circuit Court of Appeals decision pertains to a school district in Virginia, the case has bearing on House Bill 2 because the court also has jurisdiction over North Carolina along with Maryland, South Carolina and West Virginia. Legal experts say the decision has the effect of rendering unenforceable the component of HB 2 that prohibits transgender students from using school restrooms consistent with their gender identity.
Upon news of the decision, North Carolina Gov. Pat McCrory told reporters he would “make sure these court rulings are abided to,” but would need to consult with lawyers to verify the necessary approach.
“We’ve got to evaluate the impact of this court ruling on existing legislation, on existing policy that we have throughout North Carolina, and I will do just that,” McCrory said.
McCrory added he expects more action in the form of a petition for review to the U.S. Supreme Court, but meanwhile he needs to ascertain whether the ruling requires schools to allow transgender students to use public restrooms and locker rooms consistent with their gender identity, which would be contrary to House Bill 2.
“This is a major, major change in social norms not only to North Carolina, but also to the 27 other states that don’t allow this at this point in time,” McCrory said.
Signed into law last month by McCrory after an emergency session of the state legislature, HB 2 undoes all pro-LGBT non-discrimination ordinances in North Carolina, including one recently enacted in Charlotte, and prohibits transgender people from using public restrooms in schools and government buildings consistent with their gender identity.
But at the same time this law was passed, Gavin Grimm, a transgender student at Virginia’s Gloucester County High School, was appealing before the Fourth Circuit a lower court decision affirming the right of his school district’s policy barring him from using the boys restroom or locker room.
One friend-of-the-court brief was filed by the U.S. Justice Department, which argued the policy was in violation of Title IX of the Education Amendments of 1972. Another was filed by state leaders, including McCrory, and argued the court should rule in favor of the school district. Ultimately, the Fourth Circuit ruled in favor of Grimm and remanded the case to the trial court, establishing precedent in favor of transgender students.
Douglas NeJaime, faculty director of the Williams Institute at the University of California, Los Angeles, was among those saying the court decision makes unenforceable the component of HB 2 restricting bathroom use for transgender people in schools.
“The part of North Carolina’s bill that is specifically about bathrooms, or public accommodations, to the extent that they would apply to schools, which are subject to Title IX, then I think it’s suggesting in the North Carolina bill are unenforceable,” NeJaime said. “This would obviously apply to North Carolina because its in the Fourth Circuit, and the federal regulations would govern over any contrary state regulations.”
The next step in the process, NeJaime said, is for state attorneys and North Carolina Attorney General Roy Cooper, a Democrat who has refused to defend HB 2 in court, to declare that portion of the law unenforceable. If that doesn’t happen, or if Cooper and McCrory’s attorneys disagree, NeJaime said a federal court in North Carolina would make that declaration and clarify the language cannot be enforced.
“I would guess that the ACLU and Lambda attorneys would probably quite quickly file papers and ask for an injunction just on that issue fairly quickly, but then, of course, it would be up to how quickly things can be scheduled,” NeJaime said. “I would imagine that that would move forward on an accelerated schedule.”
Neither McCrory’s office nor Cooper’s responded to the Washington Blade’s request to comment late Tuesday on their determination for what the Fourth Circuit ruling means for HB 2.
Sarah Warbelow, legal director for the Human Rights Campaign, said in a statement the Fourth Circuit ruling immediately requires North Carolina to allow transgender students to use public restrooms consistent with their gender identity.
“This ruling not only gives appropriate deference to the Department of Education’s interpretation of Title IX as allowing transgender students to use school restrooms consistent with their gender identity, it also is binding on the state of North Carolina,” Warbelow said. “We therefore expect public schools, including those in North Carolina, to immediately comply, ensuring transgender students full protections under the law, which includes full access to the appropriate facilities.”
Legal groups — Lambda Legal, the American Civil Liberties Union, the ACLU of North Carolina — filed a lawsuit against HB 2 last month on the basis the law violates the equal protection and due process clauses under the Fourteenth Amendment of the U.S. Constitution and Title IX of the Education Amendments of 1972.
In a joint statement, the groups said the ruling has major implications on HB 2, but were more focused on the decision serving as an impetus for full repeal of the law.
“Today’s ruling makes plain that North Carolina’s House Bill 2 violates Title IX by discriminating against transgender students and forcing them to use the wrong restroom at school,” the statement says. “This mean-spirited law not only encourages discrimination and endangers transgender students – it puts at risk billions of dollars in federal funds that North Carolina receives for secondary and post-secondary schools. House Bill 2 exposes North Carolinians to discrimination and harm, is wreaking havoc on the state’s economy and reputation, and now more than ever, places the state’s federal education funding in jeopardy. We again call on Gov. McCrory and the General Assembly to repeal House Bill 2 and replace it with full nondiscrimination protections for LGBT people.”
Despite the different focuses of the statements, Warbelow told the Washington Blade the Human Rights Campaign and legal groups behind the lawsuit are on the same page.
“There’s no daylight between us,” Warbelow said. “North Carolina schools should follow Title IX immediately as underscored by Fourth Circuit decision. There still needs to be a full repeal of HB 2 to address its broad array of harms.”
But the ruling doesn’t have any impact on the portions of HB 2 prohibiting municipalities from enacting pro-LGBT non-discrimination ordinances, nor does it hold sway over the part that bars transgender people from using public restrooms in government buildings consistent with their gender identity.
NeJaime pointed out the Fourth Circuit ruling is based only on Title IX, which affects only students, and makes no headway into the whether equal protection and due process under the U.S. Constitution comes into play for any issue in HB 2.
“The only issue this ruling is tackling is access that trans people have to restrooms, and so the pre-emption of local non-discrimination ordinances isn’t at all impacted by this,” NeJaime added.
The district court reviewing the litigation challenging HB 2, NeJaime said, could elect to issue a more immediate ruling on use public restrooms for transgender students, but hold off until later to make a decision on other components of the law.
Although McCrory said the Gloucester County High School may seek to petition the U.S. Supreme Court for review, which could impact the result of the ruling on North Carolina, NeJaime said justices are unlikely to take action as a result of only one circuit court decision and no split among the others.
“Certainly, we saw in the marriage cases, there were cert petitions filed after preliminary injunction motions. We also saw that DOMA in litigation,” NeJaime said. “In all those cases, the court waited until there was more resolution.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
